Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - CNBC
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Search Group
Share To
Comments
About Screade
Screade® Inc. version f7eb701, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments